Albumin-binding recombinant human IL-18BP ameliorates macrophage activation syndrome and atopic dermatitis via direct IL-18 inactivation
Y.-S. Jang, K. Lee, M. Park, J. J. Park, G. M. Choi, C. Kim, S. B. Dehkohneh, S. Chi, J. Han, M. Y. Song, Y.-H. Han, S.-H. Cha, S. G. Kang
This paper develops APB-R3, a long-acting IL-18 blocker, showing efficacy in reducing inflammation in macrophage activation syndrome and atopic dermatitis models.
bioRxiv · May 30, 2023Immunology